MHAT National Heart Hospital EAD
- Address
- lock Available on a paid plan
MHAT National Heart Hospital EAD - Cardiovascular and Neurological Research Center
MHAT National Heart Hospital EAD is a distinguished clinical research institution specializing in advanced cardiovascular therapeutics and complex neurological disorders. The center demonstrates significant expertise in conducting Phase II and Phase III clinical trials, focusing on innovative treatments for chronic heart failure, pulmonary arterial hypertension, and cardiovascular disease prevention. With comprehensive research infrastructure, the hospital evaluates novel therapeutic approaches including combination therapies and long-term safety profiles across diverse patient populations.
- Heart failure management including HFpEF, HFmrEF, and chronic heart failure with renal impairment
- Pulmonary arterial hypertension treatment evaluation and long-term efficacy studies
- Multiple sclerosis therapies including relapsing multiple sclerosis and extension safety studies
- Cardiovascular disease prevention and thrombolytic interventions
The research center actively participates in groundbreaking investigations of novel pharmacological agents targeting both cardiovascular and neurological conditions. Their portfolio includes studies evaluating next-generation medications such as prostacyclin receptor agonists for PAH, endothelin receptor antagonists, aldosterone synthase inhibitors combined with SGLT2 inhibitors for heart failure, and advanced immunomodulatory therapies for multiple sclerosis. The hospital's commitment to long-term safety monitoring through open-label extension studies and rollover protocols demonstrates their dedication to comprehensive patient care and evidence-based medicine, positioning them as a key contributor to the advancement of cardiovascular and neurological therapeutics.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 80 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 80 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MHAT National Heart Hospital EAD
lock Showing 1 of 33 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 80 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Finerenone | 3 | Unknown | 2024-10-08 | 2026-04-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.